240 related articles for article (PubMed ID: 30466748)
1. Can one target T-cell ALL?
Ferrando A
Best Pract Res Clin Haematol; 2018 Dec; 31(4):361-366. PubMed ID: 30466748
[TBL] [Abstract][Full Text] [Related]
2. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
3. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
4. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.
Volanakis EJ; Williams RT; Sherr CJ
Blood; 2009 Nov; 114(20):4451-9. PubMed ID: 19759355
[TBL] [Abstract][Full Text] [Related]
5. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
7. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
8. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
9. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
[TBL] [Abstract][Full Text] [Related]
10. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia.
Wang Q; Qiu H; Jiang H; Wu L; Dong S; Pan J; Wang W; Ping N; Xia J; Sun A; Wu D; Xue Y; Drexler HG; Macleod RA; Chen S
Haematologica; 2011 Dec; 96(12):1808-14. PubMed ID: 21880637
[TBL] [Abstract][Full Text] [Related]
11. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
[TBL] [Abstract][Full Text] [Related]
12. RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications.
Gianfelici V; Chiaretti S; Demeyer S; Di Giacomo F; Messina M; La Starza R; Peragine N; Paoloni F; Geerdens E; Pierini V; Elia L; Mancini M; De Propris MS; Apicella V; Gaidano G; Testi AM; Vitale A; Vignetti M; Mecucci C; Guarini A; Cools J; Foà R
Haematologica; 2016 Aug; 101(8):941-50. PubMed ID: 27151993
[TBL] [Abstract][Full Text] [Related]
13. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia.
Herranz D; Ambesi-Impiombato A; Sudderth J; Sánchez-Martín M; Belver L; Tosello V; Xu L; Wendorff AA; Castillo M; Haydu JE; Márquez J; Matés JM; Kung AL; Rayport S; Cordon-Cardo C; DeBerardinis RJ; Ferrando AA
Nat Med; 2015 Oct; 21(10):1182-9. PubMed ID: 26390244
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A.
Karrman K; Castor A; Behrendtz M; Forestier E; Olsson L; Ehinger M; Biloglav A; Fioretos T; Paulsson K; Johansson B
J Hematol Oncol; 2015 Apr; 8():42. PubMed ID: 25903014
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
20. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
